Pairing oxygen with noninvasive ventilation at home for patients with chronic obstructive pulmonary disease (COPD) with persistent high carbon dioxide levels in the blood, who had recently had a life-threatening exacerbation requiring hospitalization, was cost effective, according to results of an abstract presented at a recent medical conference.
Pairing oxygen with noninvasive ventilation (NIV) at home for patients with chronic obstructive pulmonary disease with persistent high carbon dioxide levels in the blood, who had recently had a life-threatening exacerbation requiring hospitalization, was cost effective, according to results of an abstract presented at a recent medical conference.
In an earlier study, home oxygen therapy (HOT) combined with home noninvasive ventilation (HMV) was found to be more effective than HOT alone. The latest study looked at the cost effectiveness of the treatment and found that HOT-HMV is also less expensive.
The study, sponsored by health technology firm Royal Philips, which makes respiratory equipment, found that comparing the accumulated cost of devices, doctor visits, medication, and hospitalizations produced an average annual cost savings of $3927 per patient. The results were presented at the American Thoracic Society 2018 International Conference in San Diego, California.
Patients in the control arm were permitted to have HMV added to HOT if they had to be readmitted to the hospital and if they had persistent acidosis and an inability to wean from NIV. In the 12-month study, 28 out of 59 HOT patients and 36 out of 57 HOT-HMV patients completed the trial and 17 patients allocated to HOT received additional HMV. Hospital readmission within 30 days was 58.3% lower in the intervention group.
Costs were calculated by multiplying observed medical resource utilization by standard unit costs. The analysis indicated that the incremental cost per quality-adjusted life years (QALY) was —$50,856, suggesting that using HOT-HMV was both less expensive and more effective.
Total costs were $24,458 for HOT-HMV and $28,386 for HOT alone. For HOT-HMV, costs were $4298 for devices, $10,805 for doctor visits, $758 for medication, and $8598 for exacerbations. For HOT alone, costs were $1582, $15,033, $1088, and $10,683.
One-way sensitivity analysis suggests cost per physician visit has the greatest impact on cost/QALY. The bootstrap analysis indicates the probability for HOT-HMV to both save costs and improve quality of life is 75.7%.
Reference
Criner GJ, GU Q, Murphy PB, et al. Cost-effectiveness of home oxygen therapy-home mechanical ventilation (HOT-HMV) for treatment of chronic obstructive pulmonary disease (COPD) with chronic hypercapnic respiratory failure following an acute exacerbation of COPD in the United States. Presented at the American Thoracic Society 2018 International Conference; May 18-23, 2018; San Diego, California. Abstract A2518.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Ineligibility, Limitations to PR Uptake in Patients With AECOPD
October 15th 2024Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.
Read More